404 related articles for article (PubMed ID: 15869932)
21. Pathogenesis and animal studies of Parkinson's disease.
Oertel WH; Kupsch A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
[TBL] [Abstract][Full Text] [Related]
22. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
23. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.
Członkowska A; Kurkowska-Jastrzebska I; Członkowski A; Peter D; Stefano GB
Med Sci Monit; 2002 Aug; 8(8):RA165-77. PubMed ID: 12165754
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
Michel PP; Ruberg M; Hirsch E
Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
[TBL] [Abstract][Full Text] [Related]
25. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
26. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation.
Asanuma M; Miyazaki I
Expert Rev Neurother; 2006 Sep; 6(9):1313-25. PubMed ID: 17009919
[TBL] [Abstract][Full Text] [Related]
27. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease.
Choi HJ; Lee SY; Cho Y; No H; Kim SW; Hwang O
Neurochem Int; 2006 Mar; 48(4):255-62. PubMed ID: 16343695
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.
Reynolds AD; Banerjee R; Liu J; Gendelman HE; Mosley RL
J Leukoc Biol; 2007 Nov; 82(5):1083-94. PubMed ID: 17675560
[TBL] [Abstract][Full Text] [Related]
29. Death in the substantia nigra: a motor tragedy.
Esposito E; Di Matteo V; Di Giovanni G
Expert Rev Neurother; 2007 Jun; 7(6):677-97. PubMed ID: 17563251
[TBL] [Abstract][Full Text] [Related]
30. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
McGeer PL; Schwab C; Parent A; Doudet D
Ann Neurol; 2003 Nov; 54(5):599-604. PubMed ID: 14595649
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
32. Free radicals in Parkinson's disease.
Koutsilieri E; Scheller C; Grünblatt E; Nara K; Li J; Riederer P
J Neurol; 2002 Sep; 249 Suppl 2():II1-5. PubMed ID: 12375056
[TBL] [Abstract][Full Text] [Related]
33. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Miklossy J; Doudet DD; Schwab C; Yu S; McGeer EG; McGeer PL
Exp Neurol; 2006 Feb; 197(2):275-83. PubMed ID: 16336966
[TBL] [Abstract][Full Text] [Related]
34. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
McLaughlin P; Zhou Y; Ma T; Liu J; Zhang W; Hong JS; Kovacs M; Zhang J
Glia; 2006 Apr; 53(6):567-82. PubMed ID: 16419087
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.
Zhang D; Anantharam V; Kanthasamy A; Kanthasamy AG
J Pharmacol Exp Ther; 2007 Sep; 322(3):913-22. PubMed ID: 17565007
[TBL] [Abstract][Full Text] [Related]
36. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of nigral cell death in Parkinson's disease.
Przedborski S
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
[TBL] [Abstract][Full Text] [Related]
38. Novel anti-inflammatory therapy for Parkinson's disease.
Gao HM; Liu B; Zhang W; Hong JS
Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
40. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
